|Closing date for invited submissions / evidence submission:||TBC|
|1st appraisal committee meeting:||TBC|
|16 July 2014||
The Institute has now been informed by the manufacturer that it has withdrawn its application for a conditional marketing authorisation for vintafolide in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance